KP-001 clinical trials
Also written KP-001.
How each study uses KP-001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KP-001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KP-001
- 4
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Studies
Open first, then newest update. How each study uses KP-001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES SyndromeRecruitingPhase 3Kaken PharmaceuticalNCT07285005Written as KP-001
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001CompletedPhase 1Kaken PharmaceuticalNCT06619054Written as KP-001
- A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy AdultsCompletedPhase 1Kaken PharmaceuticalNCT06649942Written as KP-001
- Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult VolunteersCompletedPhase 1Kokua Pharma Inc.NCT06963411Written as KP001
Given beside what is tested · 2 — KP-001 is usual care or a partner of the new treatment
- To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in VolunteersCompletedPhase 1Kaken PharmaceuticalNCT06821698Written as KP-001
- A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult ParticipantsCompletedPhase 1Kaken PharmaceuticalNCT06227832Written as KP-001